Back to Annual Meeting Page		American Public Health Association 133rd Annual Meeting & Exposition December 10-14, 2005 Philadelphia, PA

Abstract #121001

Katherine E. Kemper, MBA, Future Group, GlaxoSmithKline Consumer Healthcare, 1500 Littleton Drive, Parsippany, NJ 07054, 973-889-2109, katherine.e.kemper@gsk.com

This paper will discuss the role of Corporate Social Responsibility programs. (CSR) programs within major transnational corporations. CSR programs now operate in most major transnational corporations. Is there anything wrong with such programs that can both benefit the public health while also building shareholder value? Tobacco control/smoking cessation will be presented as a specific example of where corporate and public health goals often align. However, in a large organization the impact of such focused initiatives is sometimes complicated by broader corporate policies, relationships, and/or activities in other sectors of the organization. Proposals for improving the overall positive impact of CSR initiatives in light of this complexity will be included.

Learning Objectives:

• See asession abstract

Presenting author's disclosure statement:

I wish to disclose that I have NO financial interests or other relationship with the manufactures of commercial products, suppliers of commercial services or commertial supporters WITH THE EXCEPTION OF GlaxoSmithKline employee.